Literature DB >> 27890006

Recent Updates on the Systemic and Local Safety of Intranasal Steroids.

Tae Young Jang, Young Hyo Kim1.   

Abstract

BACKGROUND: Allergic rhinitis is a global health problem, and its prevalence rate and socioeconomic burden continue to increase. Intranasal steroid (INS) is the first treatment choice in the majority of patients, because of its ability to effectively control allergic symptoms. However, patients and clinicians are concerned about the potential adverse effects of prolonged INS use.
METHODS: We performed to review for evaluating systemic and local safety of INS use, by searching MEDLINE, EMBASE, and Cochrane Library database for identification of relevant articles.
RESULTS: In the present study, the systemic bioavailabilities of several commercially available INSs were researched, and then systemic safeties were reviewed with focus on suppression of the hypothalamus-pituitary-adrenal axis and their effects on pediatric growth. In addition, local adverse effects, such as, epistaxis and nasal septal perforation, were investigated. Finally, the authors proposed some techniques in order to avoid these complications.
CONCLUSION: INSs offer a safe, effective means of treating allergic rhinitis in the short- and long-term with no or minimal adverse systemic and local effects. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Adverse effects; allergic rhinitis; biological availability; epistaxis; intranasal administration; steroids

Mesh:

Substances:

Year:  2016        PMID: 27890006     DOI: 10.2174/1389200218666161123123516

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  6 in total

1.  Submucosal thulium laser turbinoplasty in children: assessment of efficacy and comparison with partial inferior turbinectomy.

Authors:  Franck Maillet; Marie-Eva Rossi; Richard Nicollas; Eric Moreddu
Journal:  Lasers Med Sci       Date:  2022-04-06       Impact factor: 2.555

2.  Inadequate quality of administration of intranasal corticosteroid sprays.

Authors:  Corine Rollema; Eric N van Roon; Tjalling W de Vries
Journal:  J Asthma Allergy       Date:  2019-04-03

3.  Pretreatment Prediction of the Outcomes of Intranasal Steroid Sprays in Cases with Inferior Turbinate Hypertrophy.

Authors:  Abdullah Karataş
Journal:  Turk Arch Otorhinolaryngol       Date:  2017-08-14

4.  Turkish Guideline for Diagnosis and Treatment of Allergic Rhinitis (ART).

Authors:  Mustafa Cenk Ecevit; Müge Özcan; İlknur Haberal Can; Emel Çadallı Tatar; Serdar Özer; Erkan Esen; Doğan Atan; Sercan Göde; Çağdaş Elsürer; Aylin Eryılmaz; Berna Uslu Coşkun; Zahide Mine Yazıcı; Mehmet Emre Dinç; Fatih Özdoğan; Kıvanç Günhan; Nagihan Bilal; Arzu Yasemin Korkut; Fikret Kasapoğlu; Bilge Türk; Ela Araz Server; Özlem Önerci Çelebi; Tuğçe Şimşek; Rauf Oğuzhan Kum; Mustafa Kemal Adalı; Erdem Eren; Nesibe Gül Yüksel Aslıer; Tuba Bayındır; Aslı Çakır Çetin; Ayşe Enise Göker; Işıl Adadan Güvenç; Sabri Köseoğlu; Gül Soylu Özler; Ethem Şahin; Aslı Şahin Yılmaz; Ceren Güne; Gökçe Aksoy Yıldırım; Bülent Öca; Mehmet Durmuşoğlu; Yunus Kantekin; Süay Özmen; Gözde Orhan Kubat; Serap Köybaşı Şanal; Emine Elif Altuntaş; Adin Selçuk; Haşmet Yazıcı; Deniz Baklacı; Atılay Yaylacı; Deniz Hancı; Sedat Doğan; Vural Fidan; Kemal Uygur; Nesil Keleş; Cemal Cingi; Bülent Topuz; Salih Çanakçıoğlu; Metin Önerci
Journal:  Turk Arch Otorhinolaryngol       Date:  2021-05

5.  Observational study of administering intranasal steroid sprays by healthcare workers.

Authors:  Marielle de Boer; Corine Rollema; Eric van Roon; Tjalling de Vries
Journal:  BMJ Open       Date:  2020-08-30       Impact factor: 2.692

6.  Allergic rhinoconjunctivitis.

Authors:  Michele Miraglia Del Giudice; Annalisa Allegorico; Gian Luigi Marseglia; Alberto Martelli; Mauro Calvani; Fabio Cardinale; Marzia Duse; Elena Chiappini; Sara Manti; Claudio Cravidi; Maria Angela Tosca; Carlo Caffarelli
Journal:  Acta Biomed       Date:  2020-09-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.